Cancer Biology | All Life | An Open Access Journal from Taylor & Francis

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Cancer Biology

All Life

The Cancer Biology Section of All Life publishes Research, Rapid Communications, Case Reports and Reviews covering all aspects of cancer research.

In this section of All Life, we consider for publication:

Cancer Initiation, Growth and Dissemination Mechanisms

Genome and Epigenome

Metabolism and Chemical Biology

Pathophysiological Signalling

Cancer Immunology and Immunotherapy

Technologies and Models to study cancer

Tumour Biology and Cancer Stem Cells

Translational Science

Therapy Response and Resistance to Therapies

Clinical Trials

Population and Prevention Science

All Life

2019 Impact Factor 1.273

Five-Year Impact Factor 3.093


2019 CiteScore 5.50

All Life is linked with the UN’s Sustainable Development Goals. We invite researchers to share their latest research and data towards progressing solutions to Goal 3: Good Health and Well-being.

Meet the Section Editor

Editorial board for All Life

Pierre-Olivier Angrand, University of Lille, France

Pierre-Olivier Angrand is Professor in Molecular and Cell Biology at the University of Lille (France). He passed his PhD thesis at the Pasteur Institute in Paris in 1992, studying gene expression in rat hepatoma cells. After a first postdoctorate at the European Molecular Biology Laboratory (EMBL, Heidelberg, Germany) working on technologies for genome engineering, he moved to the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) in Strasbourg (France) where he discovered novel epigenetic regulators. In 2001, Pierre-Olivier Angrand was hired as a project leader in a start-up company in Heidelberg (Germany) to decipher signalling pathways using interaction proteomics. Now at the University of Lille, he has set-up a zebrafish facility aiming at developing zebrafish models of human diseases including cancer. Pierre-Olivier Angrand’s interest focuses on cancer epigenetics modelling in zebrafish.

Publicly Available Data Sharing Policy

All Life authors are required to make supporting data and materials freely available before submission in a suitable repository under any Creative Commons license.

Click below to find out more and understand the steps you need to take before submission.


Why Submit to All Life?

All Life is a fully Open Access journal to serve the ever-growing expansion of multi- and inter-disciplinary research in the life sciences:

  • Unique aims and scope welcoming truly multidisciplinary research in the life sciences (indexed in the Multidisciplinary Sciences JCR category).

  • Supporting the UN's Sustainable Development Goals for positive societal impact, providing a platform for reaching policymakers and professionals who are tackling today’s problems.

  • Pushing the boundaries of science by accepting submissions of negative/null data as well as replication and reproduction studies.

  • Promoting better information sharing through mandating public availability of all data associated with submissions.

  • Rigorous peer review process led by our team of subject experts across specialty sections.

  • Disseminating accessible and trustworthy research that has an impact on all life.

  • Indexed by EBSCOhost, Academic Search Complete, TOC Premier (Table of Contents), OCLC, Arts and Humanities Search, Ovid, Inspec, and Science Citation Index Expanded (Web of Science)

 Submit Now

Good editing leads to a great manuscript

Taylor & Francis offers a full range of pre-submission manuscript preparation services, including English language editing.

Get article alerts

Stay up to date with the latest articles by signing up to receive new content alerts.
Sign up